-
FDA Approves Shorter Infusion Time for MS Therapy Ocrevus
The U.S. Food and Drug Administration approved a shorter infusion time of Ocrevus (ocrelizumab) for people with relapsing or primary progressive MS. Read the full story here.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.